Rowan University Archives • Fragile X Research

Recruiting: Metformin Clinical Trial for Ages 16-50 with Fragile X Syndrome

FRAXA Research Foundation 2019 Grants • 2020 Grants • 2021 Grants • Clinical • Clinical Trials • Current Research Grants • McBride, Sean • Recruiting • Rowan University • University of Pennsylvania October 24, 2019March 22, 2021autism, FDA, fruit fly, metformin, sleep

FRAXA Research Foundation is funding a clinical trial of metformin for teens and adults with Fragile X syndrome. The trial is being conducted by Dr. Sean McBride at Rowan University in collaboration with colleagues at the University of Pennsylvania. Men and women ages 16-50 with Fragile X syndrome are invited to participate.

Screening 2,320 FDA-Approved Drugs for Potential Treatment of Fragile X

FRAXA Research Foundation 2018 Grants • 2019 Grants • 2020 Grants • 2021 Grants • Current Research Grants • Disease Mechanisms • Joyce, Karen • McBride, Sean • Rowan University • Treatment Targets January 9, 2019February 5, 2021autism, drug repurposing, FDA, fruit fly, lithium, metformin, mGluR, PDE4, sleep, Tetra Therapeutics

FRAXA Research Foundation has awarded a $90,000 grant to Principal Investigator Dr. Sean McBride and Postdoctoral Fellow Dr. Karen Joyce, at Rowan University, to screen all 2,320 FDA-approved drugs on both mouse and fly models of Fragile X syndrome. Those drugs which show promise will be tested in more detail for potential to treat Fragile X in humans.

Developing Fragile X Treatments in Fruit Flies and Mice

FRAXA Research Foundation 2001-2005 Grants • 2006-2010 Grants • Choi, Catherine • Completed Research Grants • Disease Mechanisms • Jongens, Tom • McBride, Sean • Rowan University • Treatment Targets February 26, 2009May 16, 2018fruit fly, lithium, LTD (Long-term depression), mGluR

With a $380,000 grant from FRAXA Research Foundation from 2005-2009, Drs. Sean McBride, Tom Jogens, and Catherine Choi studied one of the most important aspects of FRAXA’s research; the preclinical validation of potential therapeutic strategies. Many labs have found new leads for treatment. However, very few have the capacity to test new drugs in the mouse model to establish efficacy rigorously enough to lead to clinical trials. The McBride lab (in a broad collaboration with the Choi, Jongens, and Skoulakis groups) aims to do just that. Results published.